Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | AURKA | O14965 | 8/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TCF4 | P15884 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826446 | 0.90 | KDR (0.46) | KDRAURKA | |
| SCHEMBL30180545 | 0.86 | KDR (0.41) | KDRAURKAKIF11TCF4CTNNB1 | |
| SCHEMBL23999658 | 0.86 | KDR (0.41) | KDRAURKAKIF11TCF4CTNNB1 | |
| SCHEMBL25826379 | 0.83 | KDR (0.35) | KDRAURKATLR8TLR7TLR9 | |
| SCHEMBL30180637 | 0.80 | KDR (0.45) | KDRAURKATCF4CTNNB1 | |
| SCHEMBL23999674 | 0.80 | KDR (0.45) | KDRAURKATCF4CTNNB1 | |
| SCHEMBL30180266 | 0.79 | KDR (0.39) | KDRAURKATCF4CTNNB1 | |
| SCHEMBL23999443 | 0.79 | KDR (0.39) | KDRAURKATCF4CTNNB1 | |
| SCHEMBL23999653 | 0.78 | KDR (0.48) | KDRAURKA | |
| SCHEMBL30180308 | 0.78 | KDR (0.48) | KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885AURKA 2441/4885TLR8 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.